These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 14991049)

  • 21. Colchicine treatment in autosomal dominant polycystic kidney disease: many points in common.
    Solak Y; Atalay H; Polat I; Biyik Z
    Med Hypotheses; 2010 Feb; 74(2):314-7. PubMed ID: 19765912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O; Torres VE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.
    Gilbert RD; Evans H; Olalekan K; Nagra A; Haq MR; Griffiths M
    Pediatr Nephrol; 2017 May; 32(5):893-896. PubMed ID: 28194574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular polycystins: insights from autosomal dominant polycystic kidney disease and transgenic animal models.
    Bichet D; Peters D; Patel AJ; Delmas P; Honoré E
    Trends Cardiovasc Med; 2006 Nov; 16(8):292-8. PubMed ID: 17055386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.
    Di Mise A; Wang X; Ye H; Pellegrini L; Torres VE; Valenti G
    FASEB J; 2021 Oct; 35(10):e21874. PubMed ID: 34486176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case for water in the treatment of polycystic kidney disease.
    Torres VE; Bankir L; Grantham JJ
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1140-50. PubMed ID: 19443627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New therapeutic prospects in autosomal dominant polycystic kidney disease].
    Torra R
    Nefrologia; 2008; 28(3):257-62. PubMed ID: 18590491
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
    Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L
    Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
    Rapoport J
    QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
    [No Abstract]   [Full Text] [Related]  

  • 31. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adult dominant polycystic kidney disease: molecular mechanisms and new therapeutic possibilities].
    Rodríguez Pérez JC; Torres MJ
    Nefrologia; 2006; 26(6):651-2. PubMed ID: 17227240
    [No Abstract]   [Full Text] [Related]  

  • 33. Overexpression of PKD1 causes polycystic kidney disease.
    Thivierge C; Kurbegovic A; Couillard M; Guillaume R; Coté O; Trudel M
    Mol Cell Biol; 2006 Feb; 26(4):1538-48. PubMed ID: 16449663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies to inhibit cyst formation in ADPKD.
    Calvet JP
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1205-11. PubMed ID: 18434615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
    Lawson CR; Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction: new insights, treatments, and management strategies for ADPKD.
    Cowley BD
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1195-6. PubMed ID: 18322052
    [No Abstract]   [Full Text] [Related]  

  • 38. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years.
    Dicks E; Ravani P; Langman D; Davidson WS; Pei Y; Parfrey PS
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):710-7. PubMed ID: 17699277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hydration in rats and mice with polycystic kidney disease.
    Hopp K; Wang X; Ye H; Irazabal MV; Harris PC; Torres VE
    Am J Physiol Renal Physiol; 2015 Feb; 308(3):F261-6. PubMed ID: 25503729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Variable progression of autosomal dominant polycystic kidney disease: genetic and molecular counterparts].
    Devuyst O
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S104-8. PubMed ID: 17373208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.